33
Participants
Start Date
November 30, 2014
Primary Completion Date
December 31, 2017
Study Completion Date
September 30, 2018
Brentuximab vedotin
Brentuximab vedotin must not be administered as an IV push or bolus. It must be administered in 100ml-250ml of 0.9% saline by intravenous infusion over 30 minutes once every 3 weeks.
National Cancer Center, Goyang-si
Yonsei Severance Hospital, Seoul
Asan Medical Center, Seoul
Korean Cancer Center Hospital, Seoul
Collaborators (1)
Millennium Pharmaceuticals, Inc.
INDUSTRY
Samsung Medical Center
OTHER